This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/4/2026
Good morning and welcome to the United Therapeutics Corporation third quarter 2026 corporate update. My name is Krista and I will be your conference operator today. All participants on the call portion of this webcast will be in a listen only mode until the question and answer portion of this earnings call. If you would like to ask a question during that time, simply press star then the number one on your telephone keypad. and if you would like to withdraw your question, simply press star one again. Please note that this call is being recorded. I will now turn the webcast over to Harry Silvers, Investor Relations at United Therapeutics.
Thank you, Krista. Good morning, everyone. It is my pleasure to welcome you to the United Therapeutics Corporation third quarter 2026 corporate update webcast. Marks today will include forward-looking statements, representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including forms 10K and 10Q, contain additional information on these risks and uncertainties. We assume no obligation to update forward-looking statements. Today's remarks may discuss the progress and results of clinical trials or other developments with respect to our products. These remarks are intended solely to educate investors and are not intended to serve as the basis for medical decision making or to suggest that any products are safe and effective for any unapproved or investigational uses. Full prescribing information for the products is available on our website. Accompanying me on today's call are Dr. Martine Rothblatt, our chairperson and chief executive officer, Michael Benkowitz, our president and chief operating officer, James Edgemond, our chief financial officer and treasurer, Dr. Leigh Peterson, our Executive Vice President of Product Development and Xenotransplantation, and Pat Poisson, our Executive Vice President of Strategic Development. Note that James Edgemond and I will participate in a fireside chat and one-on-one sessions at the UBS Global Biopharma Conference and Jeffries Global Healthcare Conference in London on November 16th and 17th, respectively. Additionally, members from our management team will participate in a fireside chat and one-on-one meetings at the 45th Annual JPMorgan Healthcare Conference in San Francisco in January of next year. Our scientific, commercial, and medical affairs teams will be present at Phenomenal Hope 2026 on December 4th in Boston and at the Pulmonary Vascular Research Institute Annual Congress in Bangkok in late January of next year. Now, I will turn the webcast over to Martine for an overview of our development pipeline and business activities. Martine?
Thank you, Harry, and good morning everyone. We have slides available for reference, and I encourage you to review those at your leisure. I'm not going to speak directly to the slides. As we look back on the third quarter, I'm incredibly proud of what our teams have accomplished. We executed at a high level across our business and across our company, delivering for patients while advancing one of the most ambitious growth strategies in biotechnology. The significance of this quarter extends beyond any individual result or milestone. It reflects the broader transformation underway at United Therapeutics as we build a comprehensive cardiopulmonary and respiratory medicine franchise capable of reaching dramatically more patients than ever before. For most of our history, UT has been known as a pulmonary hypertension company. Today, that legacy serves as the foundation for a much bigger UT. Over the next several years, we expect to introduce wave after wave of innovation across multiple therapeutic and device platforms, from nebulized and dry powder therapies to soft mist inhalers, once daily medicines, and combination products. We have 14 programs in development. Together, these advances are intended to address some of the largest unmet needs in pulmonary fibrosis and pulmonary hypertension. We are building an integrated portfolio designed around the needs of individual patients. Our strategy is to keep innovating so we can offer more patients the right therapy in the right format at the right time. The scale of that opportunity extends far beyond our historic pulmonary hypertension market. Across IPS, PPF, and PHCOPD alone, we are pursuing patient populations totaling approximately 1 million people in the United States. Supporting this strategy are significant and durable competitive advantages. Our portfolio features extensive intellectual property protections, including fibrosis-related patents, device protections, and composition of matter protection for Relinopak. many of which extend into the 2040s. Just as important, our market advantages include decades of expertise, extensive engagement with physicians, specialized commercialization capabilities, manufacturing investments, and a proven ability to bring complex drug-device combinations to market. We are building on our strengths through the philosophy that has guided us for years. Approve, then improve. We first establish a therapy as quickly as possible because our patients do not have time. Then we continue to enhance convenience, administration, and treatment experience through new devices, formulations, and next-generation medicines. This disciplined approach creates a pipeline in which every new product builds on the foundation established by the last and provides improvements for the next. And as compelling as our cardiopulmonary and respiratory franchises are, They represent only one pillar of our long-term vision. In parallel, we continue to advance our manufactured organ alternatives programs and build the infrastructure we need to address one of medicine's greatest unmet needs. We believe this platform has the potential to revolutionize transplantation over the next decade, just as our therapies have revolutionized pulmonary hypertension over the past two decades. When I step back, I see a United Therapeutics stronger than at any point in our history, with a growing commercial business, late stage assets of significant potential, multiple upcoming launches, and a clear strategy for creating value over the long term. In closing, thank you to our fellow Unitarians, patients, physicians, shareholders, and our other stakeholders for helping us fulfill our purpose. and with that, I'll turn the call over to our president, Michael Benkowitz, for an overview of our commercial performance for the quarter.
You're reading a preview of the UTHR Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing